MiniMed logo

MiniMed

Insulin pumps, continuous glucose monitoring and automated insulin delivery.

ShareLink copied

The record

Vertical
Metabolic Health
Sub-segment
Insulin delivery and CGM
Product type
Device
Stage
Public
Headquarters
Northridge, CA, United States
Region
North America
Ticker
NASDAQ: MMED

What they do

MiniMed is a diabetes technology company listed on Nasdaq as MMED. It develops insulin pumps, continuous glucose monitoring and automated insulin delivery. On 16 November 2026 it announced FDA clearance of MiniMed Fit, its first tubeless pump, for people with Type 1 or Type 2 diabetes aged seven and older. The pump has a 300-unit capacity and up to seven days of wear, subject to insulin requirements. A phased US rollout is expected in spring 2027; clearance does not mean it is already commercially available.

History and progression

How MiniMed got here, step by step.

  1. 16 November 2026

    MiniMed Fit FDA clearance

    FDA clearance was announced for MiniMed Fit, a tubeless pump with up to seven-day wear and 300-unit capacity. A phased US rollout is planned for spring 2027.

Recent news

  1. 16 November 2026

    MiniMed announcement
  2. 16 November 2026

    Que Dallara, CEO

Related companies

Is this your company? Get a Verified profile